Psychopharmacology

, Volume 168, Issue 1–2, pp 31–41

The reinstatement model and relapse prevention: a clinical perspective

Commentary

Abstract

Objectives

This commentary assesses the degree to which the reinstatement model is homologous to the human experience of relapse.

Results

A review of the literature suggests that the relationship is less clear than is often assumed, largely due to a lack of prospective data on the precipitants and process of relapse (especially relapse to heroin or cocaine abuse). However, reinstatement does not need to resemble relapse to have immediate clinical value; predictive validity as a medication screen would be sufficient. Whether the model has predictive validity is unknown, because, to date, very few clinical trials have tested medications that are effective in the reinstatement model, and even fewer have used designs comparable to those of reinstatement experiments. A clinical trial comparable to a reinstatement experiment would enroll participants who are already abstinent, and its main outcome measure would be propensity to undergo a specific type of relapse (e.g., relapse induced by stress or cues).

Conclusions

Until clinical and preclinical work are more comparable, criticisms of the reinstatement model's presumed shortcomings are premature.

References

  1. Alleweireldt AT, Weber SM, Kirschner KF, Bullock B, Neisewander JL (2002) Blockade or stimulation of D1 dopamine receptors attenuates cue reinstatement of cocaine-seeking behavior in rats. Psychopharmacology 159:284–293CrossRefPubMedGoogle Scholar
  2. Baker DA, Tran-Nguyen TL, Fuchs RA, Neisewander JL (2001) Influence of individual differences and chronic fluoxetine treatment on cocaine-seeking behavior in rats. Psychopharmacology 155:18–26CrossRefPubMedGoogle Scholar
  3. Bergman J, Katz JL (1998) Behavioral pharmacology of cocaine and the determinants of abuse liability. In: Higgins ST, Katz JL (eds) Cocaine abuse: Behavior, pharmacology, and clinical applications. Academic Press, San Diego, pp 51–79Google Scholar
  4. Bespalov AY, Zvartau EE, Balster RL, Beardsley PM (2000) Effects of N-methyl-D-aspartate receptor antagonists on reinstatement of cocaine-seeking behavior by priming injections of cocaine or exposures to cocaine-associated cues in rats. Behav Pharmacol 11:37–44CrossRefPubMedGoogle Scholar
  5. Brady KT, Myrick H, Henderson S, Coffey SF (2002) The use of divalproex in alcohol relapse prevention: a pilot study. Drug Alcohol Depend 67:323–330CrossRefPubMedGoogle Scholar
  6. Campbell UC, Lac ST, Carroll ME (1999) Effects of baclofen on maintenance and reinstatement of intravenous cocaine self-administration in rats. Psychopharmacology 143:209–214CrossRefPubMedGoogle Scholar
  7. Ciccocioppo R, Sanna PP, Weiss F (2001) Cocaine-predictive stimulus induces drug-seeking behavior and neural activation in limbic brain regions after multiple months of abstinence: reversal by D(1) antagonists. Proc Natl Acad Sci USA 98:1976–1981CrossRefPubMedCentralPubMedGoogle Scholar
  8. Ciccocioppo R, Martin-Fardon R, Weiss F (2002) Effect of selective blockade of μ1 or δ opioid receptors on reinstatement of alcohol-seeking behavior by drug-associated stimuli in rats. Neuropsychopharmacology 27:391-399CrossRefPubMedGoogle Scholar
  9. Comer SD, Lac ST, Curtis LK, Carroll ME (1993) Effects of buprenorphine and naltrexone on reinstatement of cocaine-reinforced behavior. J Pharmacol Exp Ther 267:1470–1477PubMedGoogle Scholar
  10. Compton PA, Ling W, Charuvastra VC, Wesson DR (1995) Buprenorphine as a pharmacotherapy for cocaine abuse: a review of the evidence. J Addict Dis 14:97–114CrossRefPubMedGoogle Scholar
  11. CRISP Database Of Federally Funded Biomedical Research Projects (2003) http://crisp.cit.nih.gov. Cited 13 Feb 2003Google Scholar
  12. Crombag H, Grimm JW, Shaham Y (2002) Effect of dopamine receptor antagonists on renewal of cocaine seeking by re-exposure to drug-associated contextual cues. Neuropsychopharmacology 27:1006–1015CrossRefPubMedGoogle Scholar
  13. De Vries TJ, Shaham Y, Homberg JR, Crombag H, Schuurman K, Dieben J, Vanderschuren LJ, Schoffelmeer AN (2001) A cannabinoid mechanism in relapse to cocaine seeking. Nat Med 7:1151–1154CrossRefGoogle Scholar
  14. Erb S, Shaham Y, Stewart J (1998) The role of corticotropin-releasing factor and corticosterone in stress- and cocaine-induced relapse to cocaine seeking in rats. J Neurosci 18:5529–5536PubMedGoogle Scholar
  15. Erb S, Hitchcott PK, Rajabi H, Mueller D, Shaham Y, Stewart J (2000) Alpha-2 adrenergic agonists block stress-induced reinstatement of cocaine seeking. Neuropsychopharmacology 23:138–150CrossRefPubMedGoogle Scholar
  16. Ettenberg A, MacConell LA, Geist TD (1996) Effects of haloperidol in a response-reinstatement model of heroin relapse. Psychopharmacology 124:205–210CrossRefPubMedGoogle Scholar
  17. Freedman M, Pulley L, Abdolrussa B, McNamara C, Milby J, Schumacher J (2002) Ecological momentary assessment of crack cocaine relapse risk. In: 64th annual scientific meeting of the college on problems of drug dependence, San Juan, Puerto Rico. http://biopsych.com:81/cpdd02_web. Cited 13 Feb 2003Google Scholar
  18. Gallin JI, Gottesman MM (2003) Bench-to-bedside awards. National Institutes of Health, Bethesda, MD. http://www.cc.nih.gov/ccc/btb/awards.html. Cited 10 March 2003Google Scholar
  19. Gosnell BA (2000) The effects of sucrose availability on the reinstatement of cocaine-seeking. Soc Neurosci Abstr 485.16Google Scholar
  20. Gottlieb LD, Horwitz RI, Kraus ML. Segal SR, Viscoli CM (1994) Randomized controlled trial in alcohol relapse prevention: role of atenolol, alcohol craving, and treatment adherence. J Subst Abuse Treat 11:253–258CrossRefPubMedGoogle Scholar
  21. Grimm JW, Hope BT, Wise RA, Shaham Y (2001) Neuroadaptation: incubation of cocaine craving after withdrawal. Nature 412:141–142Google Scholar
  22. Grottick AJ, Fletcher PJ, Higgins GA (2000) Studies to investigate the role of 5-HT2C receptors on cocaine and food maintained behaviour. J Pharmacol Exp Ther 295:1183–1191PubMedGoogle Scholar
  23. Gruber K, Chutuape MA, Stitzer ML (2000) Reinforcement-based intensive outpatient treatment for inner city opiate abusers: a short-term evaluation. Drug Alcohol Depend 57: 211–223CrossRefPubMedGoogle Scholar
  24. Hall SM, Havassy BE, Wasserman DA (1991) Effects of commitment to abstinence, positive moods, stress, and coping on relapse to cocaine use. J Cons Clin Psychol 59: 526–532CrossRefGoogle Scholar
  25. Handelsman L, Rosenblum A, Palij M, Magura S, Foote J, Lovejoy M, Stimmel B (1997) Bromocriptine for cocaine dependence: a controlled clinical trial. Am J Addict 6: 54–64PubMedGoogle Scholar
  26. Haney M, Collins ED, Ward AS, Foltin RW, Fischman MW (1999) Effect of a selective dopamine D1 agonist (ABT-431) on smoked cocaine self-administration in humans. Psychopharmacology 143:102–110CrossRefPubMedGoogle Scholar
  27. Haney M, Ward AS, Foltin RW, Fischman MW (2001) Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans. Psychopharmacology 155:330–337CrossRefPubMedGoogle Scholar
  28. Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ, Sachs DPL, Wolter TD, Buist AS, Johnston JA, White JD (2001) Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation: a randomized, controlled trial. Ann Intern Med 135:423–433CrossRefPubMedGoogle Scholar
  29. Heyser CJ, Schulteis G, Durbin P, Koob GF (1998) Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats. Neuropsychopharmacology 18:125–133CrossRefPubMedGoogle Scholar
  30. Highfield D, Yap J, Grimm J, Shalev U, Shaham Y (2001) Repeated lofexidine treatment attenuates stress-induced, but not drug cues-induced reinstatement of a heroin-cocaine mixture (speedball) seeking in rats. Neuropsychopharmacology 25:320–331CrossRefPubMedGoogle Scholar
  31. Hiller ML (1996) Correlates of recidivism and relapse for parolees who received in-prison substance abuse treatment in Texas. In: Dissertation abstracts international: Section b: The sciences and engineering, vol 57(4-B):2866 Univ Microfilms International, USAGoogle Scholar
  32. Holter SM, Landgraf R, Zieglgansberger W, Spanagel R (1997) Time course of acamprosate action on operant ethanol self-administration after ethanol deprivation. Alcohol Clin Exp Res 21:862–868CrossRefPubMedGoogle Scholar
  33. Khroyan TV, Barrett-Larimore RL, Rowlett JK, Spealman RD (2000) Dopamine D1- and D2-like receptor mechanisms in relapse to cocaine-seeking behavior: effects of selective antagonists and agonists. J Pharmacol Exp Ther 294:680–687PubMedGoogle Scholar
  34. Kosten TS, Oliveto A, Sevarino KA, Gonsai K, Feingold A (2002) Ketoconazole increases cocaine and opioid use in methadone maintained patients Drug Alcohol Depend 66:173–180CrossRefGoogle Scholar
  35. Kranzler HR, Burleson JA, Korner P, Del Boca FK, Bohn MJ, Brown J, Liebowitz N (1995) Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry 152:391–397CrossRefPubMedGoogle Scholar
  36. Lando HA, Valanis BG, Lichtenstein E, Curry SJ, McBride CM, Pirie PL, Grothaus LC (2001) Promoting smoking abstinence in pregnant and postpartum patients: a comparison of 2 approaches. Am J Manag Care 7:685–693PubMedGoogle Scholar
  37. Latt NC, Jurd S, Houseman J, Wutzke SE (2002) Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med J Australia 176:530–534PubMedGoogle Scholar
  38. Lê AD, Poulos CX, Harding S, Watchus J, Juzytsch W, Shaham Y (1999) Effects of naltrexone and fluoxetine on alcohol self-administration and reinstatement of alcohol seeking induced by priming injections of alcohol and exposure to stress. Neuropsychopharmacology 21:435–444CrossRefPubMedGoogle Scholar
  39. Lê AD, Shaham Y (2002) Neurobiology of relapse to alcohol in rats. Pharmacol Therapeut 94:137–156CrossRefGoogle Scholar
  40. Lindblom N, De Villiers SH, Kalayanov G, Gordon S, Johansson AM, Svensson TH (2002) Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration 69:254–260CrossRefPubMedGoogle Scholar
  41. Ling W, Shoptaw S, Majewska D (1998) Baclofen as a cocaine anti-craving medication: a preliminary clinical study. Neuropsychopharmacology 18:403–404CrossRefPubMedGoogle Scholar
  42. Litt MD, Cooney NL, Morse P (1998) Ecological Momentary Assessment (EMA) with treated alcoholics: methodological problems and potential solutions. Health Psychol 17:48–52CrossRefPubMedGoogle Scholar
  43. Litt MD, Cooney NL, Morse P (2000) Reactivity to alcohol-related stimuli in the laboratory and in the field: predictors of craving in treated alcoholics. Addiction 95:889–900CrossRefPubMedGoogle Scholar
  44. Liu X, Weiss F (2002a) Reversal of ethanol-seeking behavior by D1 and D2 antagonists in an animal model of relapse: differences in antagonist potency in previously ethanol-dependent versus nondependent rats. J Pharmacol Exp Ther 300:882–889CrossRefPubMedGoogle Scholar
  45. Liu X, Weiss F (2002b) Additive effect of stress and drug cues on reinstatement of ethanol seeking: exacerbation by history of dependence and role of concurrent activation of corticotropin-releasing factor and opioid mechanisms. J Neurosci 22:7856–7861PubMedGoogle Scholar
  46. Longo LP (2002) Olanzapine for cocaine craving and relapse prevention in 2 patients. J Clin Psychiatry 63:595–596CrossRefPubMedGoogle Scholar
  47. Longo LP, Campbell T, Hubatch S (2002) Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention. J Addictive Diseases 21:55–64CrossRefGoogle Scholar
  48. Lukas SE, Stull M, Cowan RL (2002) Polydrug abuse patterns with MDMA (Ecstasy) among young adults. Drug Alcohol Depend 66(suppl 1):S107CrossRefGoogle Scholar
  49. Mantsch JR, Goeders NE (1999a) Ketoconazole does not block cocaine discrimination or the cocaine-induced reinstatement of cocaine-seeking behavior. Pharmacol Biochem Behav 64:65–73CrossRefPubMedGoogle Scholar
  50. Mantsch JR, Goeders NE (1999b) Ketoconazole blocks the stress-induced reinstatement of cocaine-seeking behavior in rats: relationship to the discriminative stimulus effects of cocaine. Psychopharmacology 142:399–407CrossRefPubMedGoogle Scholar
  51. Margolin A, Avants SK, Kosten TR (1995) Mazindol for relapse prevention to cocaine abuse in methadone-maintained patients. Am J Drug Alcohol Abuse 21:469–481CrossRefPubMedGoogle Scholar
  52. Marlatt AG (1996) Models of relapse and relapse prevention: a commentary. Exp Clin Psychopharmacol 4:55–60Google Scholar
  53. Martin-Fardon R, Ciccocioppo R, Massi M, Weiss F (2000) Nociceptin prevents stress-induced ethanol, but not cocaine-seeking behavior in rats. Neuroreport 11:1939–1943CrossRefPubMedGoogle Scholar
  54. McBride CM, Curry SJ, Lando HA, Pirie PL, Grothaus LC, Nelson JC (1999) Prevention of relapse in women who quit smoking during pregnancy. Am J Public Health 89:706–711CrossRefPubMedCentralPubMedGoogle Scholar
  55. McCrady BS, Epstein EE, Hirsch LS (1999) Maintaining change after conjoint behavioral alcohol treatment for men: outcomes at 6 months. Addiction 94:1381–1396CrossRefPubMedGoogle Scholar
  56. McElroy SL, Weiss RD, Mendelson JH, Teoh SK, McAfee B, Mello NK (1989) NIDA Research Monograph 95:57–63PubMedGoogle Scholar
  57. McKay JR, Alterman AI, Cacciola JS, Rutherford MJ, O'Brien CP, Koppenhaver J (1997) Group counseling versus individualized relapse prevention aftercare following intensive outpatient treatment for cocaine dependence: initial results. J Cons Clin Psychol 65:778–788CrossRefGoogle Scholar
  58. McMahon RC (2001) Personality, stress, and social support in cocaine relapse prediction. J Subst Abuse Treat 21:77–87CrossRefPubMedGoogle Scholar
  59. Montoya ID, Gorelick DA, Preston KL, Umbricht A, Cheskin L, Contoreggi C, Johnson RE, Fudala PJ (1996) Buprenorphine for treatment of dually-dependent (opiate and cocaine) individuals. NIDA Research Monograph 162:178Google Scholar
  60. Montoya ID, Preston KL, Rothman R, Gorelick DA (2002) Open-label pilot study of bupropion plus bromocriptine for treatment of cocaine dependence. Am J Drug Alc Abuse 28:189–196CrossRefGoogle Scholar
  61. Nader MA, Woolverton WL (1991) Effects of increasing the magnitude of an alternative reinforcer on drug choice in a discrete-trials choice procedure. Psychopharmacology 105:169–174Google Scholar
  62. Niaura R, Abrams DR, Shadel WG, Rohsenow DJ, Monti PM, Sirota AD (1999) Addiction 94:685–695CrossRefPubMedGoogle Scholar
  63. Norman AB, Norman MK, Hall JF, Tsibulsky VL (1999) Priming threshold: a novel quantitative measure of the reinstatement of cocaine self-administration. Brain Res 831:165–174CrossRefPubMedGoogle Scholar
  64. Romach MK, Glue P,Kampman K, Kaplan HL, Somer GR, Poole S, Clarke L, Coffin V, Cornish J, O'Brien CP, Sellers EM (1999) Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166). Arch Gen Psychiat 56:1101–1106CrossRefPubMedGoogle Scholar
  65. Sarter M, Hagan J, Dudchenko P (1992) Behavioral screening for cognition enhancers: from indiscriminate to valid testing: part 1. Psychopharmacology 107:144–159CrossRefPubMedGoogle Scholar
  66. Sarter M, Bruno JP (2002) Animal models in biological psychiatry. In: D'haenen H, den Boer JA, Willner P (eds) Biological psychiatry. Wiley, New York, pp 37–44Google Scholar
  67. Sass H, Soyka M, Mann K, Zieglgansberger W (1996) Relapse prevention by acamprosate: results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiat 53:673–680CrossRefPubMedGoogle Scholar
  68. Schenk S (2000) Effects of the serotonin 5-HT(2) antagonist, ritanserin, and the serotonin 5-HT(1A) antagonist, WAY 100635, on cocaine-seeking in rats. Pharmacol Biochem Behav 67:363–369CrossRefPubMedGoogle Scholar
  69. Schenk S, Partridge B, Shippenberg TS (1999) U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking. Psychopharmacology 144:339–346CrossRefPubMedGoogle Scholar
  70. Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR (1997) Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiat 54:713–720CrossRefPubMedGoogle Scholar
  71. Schmidt LG, Kuhn S, Smolka M, Schmidt K, Rommelspacher H (2002) Lisuride, a dopamine D2 receptor agonist, and anticraving drug expectancy as modifiers of relapse in alcohol dependence. Prog Neuro-Psychopharmacol Biol Psych 26:209–217Google Scholar
  72. Schmitz JM, Stotts AL, Rhoades HM, Grabowski J (2001) Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict Behav 26:167–180CrossRefPubMedGoogle Scholar
  73. See RE, Kruzich PJ, Grimm JW (2001) Dopamine, but not glutamate, receptor blockade in the basolateral amygdala attenuates conditioned reward in a rat model of relapse to cocaine-seeking behavior. Psychopharmacology 154:301–310CrossRefPubMedGoogle Scholar
  74. Self DW, Barnhart WJ, Lehman DA, Nestler EJ (1996) Opposite modulation of cocaine-seeking behavior by D1- and D2-like dopamine receptor agonists. Science 271:1586–1589CrossRefPubMedGoogle Scholar
  75. Self DW, Karanian DA, Spencer JJ (2000) Effects of the novel D1 dopamine receptor agonist ABT-431 on cocaine self-administration and reinstatement. Ann NY Acad Sci 909:133–144CrossRefPubMedGoogle Scholar
  76. Shaham Y, Stewart J (1996) Effects of opioid and dopamine receptor antagonists on relapse induced by stress and re-exposure to heroin in rats. Psychopharmacology 125:385–391CrossRefPubMedGoogle Scholar
  77. Shaham Y, Funk D, Erb S, Brown TJ, Walker CD, Stewart J (1997) Corticotropin-releasing factor, but not corticosterone, is involved in stress-induced relapse to heroin-seeking in rats. J Neurosci 17:2605–2614PubMedGoogle Scholar
  78. Shaham Y, Erb S, Leung S, Buczek Y, Stewart J (1998) CP-154,526, a selective, non peptide antagonist of the corticotropin-releasing factor type 1 receptor attenuates stress-induced relapse to drug seeking in cocaine-and heroin-trained rats. Psychopharmacology 137:184–190CrossRefPubMedGoogle Scholar
  79. Shaham Y, Highfield D, Delfs JM, Leung S, Stewart J (2000) Clonidine blocks stress-induced reinstatement of heroin seeking in rats: an effect independent of the locus coeruleus noradrenergic neurons. Eur J Neurosci 12:292–302CrossRefPubMedGoogle Scholar
  80. Shaham Y, Shalev U, Lu L, de Wit H, Stewart J (2003) The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology DOI 10.1007/s00213-002-1224-xGoogle Scholar
  81. Shalev U, Yap J, Shaham Y (2001) Leptin attenuates food deprivation-induced relapse to heroin seeking. J Neurosci 21:RC129PubMedGoogle Scholar
  82. Shalev U, Grimm JW, Shaham Y (2002) Neurobiology of relapse to heroin and cocaine: a review. Pharmacol Rev 54:1-42CrossRefPubMedGoogle Scholar
  83. Shiffman S, Paty JA, Gnys M, Kassel JD, Hickcox M (1996) First lapses to smoking: within-subjects analysis of real-time reports. J Cons Clin Psychol 64:366–379CrossRefGoogle Scholar
  84. Shiffman S, Hufford M, Hickcox M, Paty JA, Gnys M, Kassel JD (1997) Remember that? a comparison of real-time versus retrospective recall of smoking lapses. J Cons Clin Psychol 65:292–300CrossRefGoogle Scholar
  85. Sidman M (1960) Tactics of scientific research: evaluating experimental data in psychology. Basic Books, New YorkGoogle Scholar
  86. Spanagel R, Holter SM, Allingham K, Landgraf R (1996) Acamprosate and alcohol: 1. effects on alcohol intake following alcohol deprivation in the rat. Eur J Pharmacol 305:39–44CrossRefPubMedGoogle Scholar
  87. Spanagel R, Sillaber A, Zieglgansberger W, Corrigall WA, Stewart J, Shaham Y (1998) Acamprosate suppresses the expression of morphine-induced sensitization in rats but does not affect heroin self-administration or relapse. Psychopharmacology 139:391–401CrossRefPubMedGoogle Scholar
  88. Streeton C, Whelan G (2001) Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcoholism 36:544–552CrossRefPubMedGoogle Scholar
  89. Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A (2000) Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcoholism 35:202–209CrossRefPubMedGoogle Scholar
  90. Teoh SK, Mello NK, Mendelson JH, Kuehnle J, Gastfriend DR, Rhoades E, Sholar W (1994) Buprenorphine effects on morphine- and cocaine-induced subjective responses by drug-dependent men. J Clin Psychopharmacol 14:15–27CrossRefPubMedGoogle Scholar
  91. Wasserman DA, Weinstein MG, Havassy BE, Hall SM (1998) Factors associated with lapses to heroin use during methadone maintenance. Drug Alcohol Depend 52:183–192CrossRefPubMedGoogle Scholar
  92. Weiss RD, Griffin ML, Hufford C (1995) Craving in hospitalized cocaine abusers as a predictor of outcome. Am J Drug Alc Abuse 21:289–301CrossRefGoogle Scholar
  93. Widom CS, Weiler BL, Cottler LB (1999) Childhood victimization and drug abuse: a comparison of prospective and retrospective findings. J Cons Clin Psychol 67:867–880CrossRefGoogle Scholar
  94. Wiesbeck GA, Weijers HG, Chick J, Naranjo CA, Boening J (1999) Ritanserin in relapse prevention in abstinent alcoholics: results from a placebo-controlled double-blind international multicenter trial. Alcohol Clin Exp Res 23:230–235PubMedGoogle Scholar
  95. Wiesbeck GA, Weijers HG, Lesch OM, Glaser T, Toennes PJ, Boening J (2001) Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study. Alcohol Alcoholism 36:329–334CrossRefPubMedGoogle Scholar
  96. Wise RA, Murray A, Bozarth MA (1990) Bromocriptine self-administration and bromocriptine-reinstatement of cocaine-trained and heroin-trained lever pressing in rats. Psychopharmacology 100:355–360CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  1. 1.NIDA/IRP Treatment Section, Intramural Research ProgramNational Institute on Drug AbuseBaltimoreUSA

Personalised recommendations